FIELD: biotechnology.
SUBSTANCE: single-domain H5 llama antibody that specifically binds to the RBD-domain of the S-protein of the SARS-CoV-2 virus and has virus-neutralizing activity, and a chimeric H5-Fc antibody are described. In one embodiment, the single domain antibody has the amino acid sequence of SEQ ID NO: 1 encoded by the nucleotide sequence of SEQ ID NO: 3 and has complementarity determining regions (CDRs) with the amino acid sequences of SEQ ID NO: 5–7.
EFFECT: invention makes it possible to obtain high-affinity antibodies recognizing the RBD-domain of SARS-CoV-2 and to use them for diagnostics, therapy and prevention of coronavirus infection caused by SARS-CoV-2 in humans and other mammals.
2 cl, 7 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| POLYPEPTIDE MODULE FOR BINDING CONSERVATIVE EPITOPE OF RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 CORONAVIRUS | 2022 |
|
RU2809183C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) | 2022 |
|
RU2777404C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
